FDA Panel Endorses Liraglutide as Obesity TreatmentFDA Panel Endorses Liraglutide as Obesity Treatment
An FDA committee voted 14 to 1 in favor of liraglutide as an obesity treatment, stipulating that lingering safety questions be addressed in postmarketing studies. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 12, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity
WASHINGTON (Reuters) - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - September 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Panel Gives Nod to Novo Nordisk Diabetes Drug for Weight Loss
(MedPage Today) -- COLLEGE PARK, Md. -- An FDA advisory committee recommended Thursday that injectable liraglutide (Saxenda) be approved for the treatment of obesity. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 12, 2014 Category: American Health Source Type: news
U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity
WASHINGTON (Reuters) - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - September 11, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Data demonstrates 'efficacy and tolerability' of IDegLira
Diabetes Care has published phase IIIa findings that demonstrate a significantly greater glucose-lowering effect with IDegLira compared with insulin degludec. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 11, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Diabetes IDegLira insulin degludec/liraglutide Latest News type 2 diabetes Xultophy Source Type: news
Byetta Lawsuit News: New Order Establishes Deposition Protocol For...
The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb August 10, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12083571.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 10, 2014 Category: Pharmaceuticals Source Type: news
CHMP positive opinion for Xultophy?
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency has adopted a positive opinion for Xultophy, the first-ever once-daily basal insulin (insulin degludec, Tresiba)
and GLP-1 analogue (liraglutide, Victoza) in one pen. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 28, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Diabetes Featured Articles Tresiba Xultophy Source Type: news
Novo wins EU recommendation for two-in-one diabetes drug
LONDON (Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company. (Source: Reuters: Health)
Source: Reuters: Health - July 25, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Once-Weekly Dulaglutide Is Noninferior to Daily LiraglutideOnce-Weekly Dulaglutide Is Noninferior to Daily Liraglutide
In a rare head-to-head trial of two GLP-1 receptor agonists, once-weekly dulaglutide was similar to once-daily liraglutide in efficacy and tolerability. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 24, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
ADA: Victoza Lowers Glucose in Genetic Form of Diabetes (CME/CE)
SAN FRANCISCO (MedPage Today) -- Liraglutide (Victoza) works roughly as well as standard sulfonylurea treatment for an inherited type of diabetes but with less hypoglycemia, a small trial showed. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - June 23, 2014 Category: Pediatrics Source Type: news
New Weight-Loss Drugs: When to Prescribe?New Weight-Loss Drugs: When to Prescribe?
Dr. Steven Smith reviews 2 weight-loss drugs in the pipeline, liraglutide and naltrexone/bupropion, and discusses how to prescribe such drugs and appropriate patients to receive them. Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news
Once-Weekly Dulaglutide Effective for T2DMOnce-Weekly Dulaglutide Effective for T2DM
Dr. Anne Peters and Dr. Kathleen Dungan discuss results of an open-label trial comparing weekly dulaglutide with daily liraglutide in type 2 diabetes. Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news
ADA: Weekly GLP-1 Agonist Matches Daily Victoza in T2D
SAN FRANCISCO (MedPage Today) -- The investigational weekly GLP-1 agonist dulaglutide improved glycemic control in type 2 diabetes comparably to daily liraglutide (Victoza) but with less weight loss, researchers reported here. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 17, 2014 Category: Primary Care Source Type: news
Novo Nordisk Type 2 Diabetes Drug Increases Weight Loss
Late-stage clinical trial shows patients taking Victoza reported a mean loss of 5.9 percent of body weight (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 16, 2014 Category: Pharmaceuticals Source Type: news
ADA: Victoza Lowers Glucose in Genetic Form of Diabetes
SAN FRANCISCO (MedPage Today) -- Liraglutide (Victoza) works roughly as well as standard sulfonylurea treatment for an inherited type of diabetes but with less hypoglycemia, a small trial showed. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - June 15, 2014 Category: Pediatrics Source Type: news
